Sequential high-dose ifosfamide, carboplatin and etoposide with rituximab for relapsed Hodgkin and large B-cell non-Hodgkin lymphoma: increased toxicity without improvement in progression-free survival

References

• Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun M J. Cancer statistics, 2007. CA Cancer J Clin 2007; 57: 43–66
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235–242
   PubMed Web of Science ®Google Scholar
• Gobbi P G, Levis A, Chisesi T, Broglia C, Vitolo U, Stelitano C, et al. ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi. J Clin Oncol 2005; 23: 9198–9207
   PubMed Web of Science ®Google Scholar
• Josting A, Sieniawski M, Glossmann J P, Staak O, Nogova L, Peters N, et al. High-dose sequential chemotherapy followed by autologous stem cell transplantation in relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a multicenter phase II study. Ann Oncol 2005; 16: 1359–1365
   PubMed Web of Science ®Google Scholar
• Schmitz N, Pfistner B, Sextro M, Sieber M, Carella A M, Haenel M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet 2002; 359: 2065–2071
   PubMed Web of Science ®Google Scholar
• Shipp M G, Abeloff M D, Antman K H, Carroll G, Hagenbeek A, Loeffler M, et al. International consensus conference on high-dose therapy with hematopoietic stem-cell transplantation in aggressive non-Hodgkin's lymphomas: report of the jury. Ann Oncol 1999; 10: 13–19
   PubMed Web of Science ®Google Scholar
• Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333: 1540–1545
   PubMed Web of Science ®Google Scholar
• Kewalramani T, Zelenetz A D, Nimer S D, Portlock C, Straus D, Noy A, et al. Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood 2004; 103: 3684–3688
   PubMed Web of Science ®Google Scholar
• Moskowitz C G, Bertino J R, Glassman J R, Hedrick E E, Hunte S, Coady-Lyons N, et al. Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma. J Clin Oncol 1999; 17: 3776–3785
   PubMed Web of Science ®Google Scholar
• Hertzberg M G, Crombie C, Benson W, Taper J, Gottlieb D, Bradstock K F. Outpatient fractionated ifosfamide, carboplatin and etoposide as salvage therapy in relapsed and refractory non-Hodgkin's and Hodgkin's lymphoma. Ann Oncol 2006; 17(Suppl. 4)iv25–iv30
   PubMed Web of Science ®Google Scholar
• Zelenetz A G, Hamlin P, Kewalramani T, Yahalom J, Nimer S, Moskowitz C H. Ifosfamide, carboplatin, etoposide (ICE)-based second-line chemotherapy for the management of relapsed and refractory aggressive non-Hodgkin's lymphoma. Ann Oncol 2003; 14(Suppl. 1)i5–i10
   PubMed Web of Science ®Google Scholar
• Jerkeman M, Leppa S, Kvaloy S, Holte H. ICE (ifosfamide, carboplatin, etoposide) as second-line chemotherapy in relapsed or primary progressive aggressive lymphoma – the Nordic lymphoma group experience. Eur J Haematol 2004; 73: 179–182
   PubMed Web of Science ®Google Scholar
• Norton L, Simon R. Tumor size, sensitivity to therapy, and design of treatment schedules. Cancer Treat Rep 1977; 61: 1307–1317
   PubMedGoogle Scholar
• Norton L, Simon R. The Norton-Simon hypothesis revisited. Cancer Treat Rep 1986; 70: 163–169
   PubMedGoogle Scholar
• Gianni A G, Bregni M, Siena S, Brambilla C, Di Nicola M, Lombardi F, et al. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N Engl J Med 1997; 336: 1290–1297
   PubMed Web of Science ®Google Scholar
• Gianni A G, Siena S, Bregni M, Di Nicola M, Orefice S, Cusumano F, et al. Efficacy, toxicity, and applicability of high-dose sequential chemotherapy as adjuvant treatment in operable breast cancer with 10 or more involved axillary nodes: five-year results. J Clin Oncol 1997; 15: 2312–2321
   PubMed Web of Science ®Google Scholar
• Bonadonna G, Zambetti M, Valagussa P. Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. Ten-year results. JAMA 1995; 273: 542–547
   PubMed Web of Science ®Google Scholar
• Le Cesne A, Antoine E, Spielmann M, Le Chevalier T, Brain E, Toussaint C, et al. High-dose ifosfamide: circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas. J Clin Oncol 1995; 13: 1600–1608
   PubMed Web of Science ®Google Scholar
• Hudis C, Fornier M, Riccio L, Lebwohl D, Crown J, Gilewski T, et al. 5-year results of dose-intensive sequential adjuvant chemotherapy for women with high-risk node-positive breast cancer: a phase II study. J Clin Oncol 1999; 17: 1118
   PubMed Web of Science ®Google Scholar
• Citron M G, Berry D A, Cirrincione C, Hudis C, Winer E P, Gradishar W J, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of intergroup trial C9741/cancer and leukemia group B trial 9741. J Clin Oncol 2003; 21: 1431–1439
   PubMed Web of Science ®Google Scholar
• Wood W G, Budman D R, Korzun A H, Cooper M R, Younger J, Hart R D, et al. Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med 1994; 330: 1253–1259
   PubMed Web of Science ®Google Scholar
• Haioun C, Lepage E, Gisselbrecht C, Bastion Y, Coiffier B, Brice P, et al. Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin's lymphoma: updated results of the prospective study LNH87-2. Groupe d'etude des lymphomes de l'adulte. J Clin Oncol 1997; 15: 1131–1137
   PubMed Web of Science ®Google Scholar
• Prince H G, Imrie K, Crump M, Stewart A K, Girouard C, Colwill R, et al. The role of intensive therapy and autologous blood and marrow transplantation for chemotherapy-sensitive relapsed and primary refractory non-Hodgkin's lymphoma: identification of major prognostic groups. Br J Haematol 1996; 92: 880–889
   PubMed Web of Science ®Google Scholar
• Vose J G, Zhang M J, Rowlings P A, Lazarus H M, Bolwell B J, Freytes C O, et al. Autologous transplantation for diffuse aggressive non-Hodgkin's lymphoma in patients never achieving remission: a report from the autologous blood and marrow transplant registry. J Clin Oncol 2001; 19: 406–413
   PubMed Web of Science ®Google Scholar
• Lazarus H G, Rowlings P A, Zhang M J, Vose J M, Armitage J O, Bierman P J, et al. Autotransplants for Hodgkin's disease in patients never achieving remission: a report from the autologous blood and marrow transplant registry. J Clin Oncol 1999; 17: 534–545
   PubMed Web of Science ®Google Scholar
• Simon R, Norton L. The Norton-Simon hypothesis: designing more effective and less toxic chemotherapeutic regimens. Nat Clin Pract Oncol 2006; 3: 406–407
   PubMedGoogle Scholar
• Goldie J H, Coldman A J. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 1979; 63: 1727–1733
   PubMedGoogle Scholar